| Literature DB >> 32183492 |
Henricus J B Janssen1, Laura F C Fransen1, Jeroen E H Ponten1, Grard A P Nieuwenhuijzen1, Misha D P Luyer1.
Abstract
Over the past decades, survival rates for patients with resectable esophageal cancer have improved significantly. Consequently, the sequelae of having a gastric conduit, such as development of micronutrient deficiencies, become increasingly apparent. This study investigated postoperative micronutrient trends in the follow-up of patients following a minimally invasive esophagectomy (MIE) for cancer. Patients were included if they had at least one postoperative evaluation of iron, ferritin, vitamins B1, B6, B12, D, folate or methylmalonic acid. Data were available in 83 of 95 patients. Of these, 78.3% (65/83) had at least one and 37.3% (31/83) had more than one micronutrient deficiency at a median of 6.1 months (interquartile range (IQR) 5.4-7.5) of follow-up. Similar to the results found in previous studies, most common deficiencies identified were: iron, vitamin B12 and vitamin D. In addition, folate deficiency and anemia were detected in a substantial amount of patients in this cohort. At 24.8 months (IQR 19.4-33.1) of follow-up, micronutrient deficiencies were still common, however, most deficiencies normalized following supplementation on indication. In conclusion, patients undergoing a MIE are at risk of developing micronutrient deficiencies as early as 6 up to 24 months after surgery and should therefore be routinely checked and supplemented when needed.Entities:
Keywords: esophageal cancer; esophagectomy; micronutrient deficiencies; vitamin deficiencies
Mesh:
Substances:
Year: 2020 PMID: 32183492 PMCID: PMC7146612 DOI: 10.3390/nu12030778
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Overview of the current literature on micronutrient deficiencies following esophagectomy.
| Author | Country | Year | Study Period | Study Design | Study population | Type of Surgery | Follow-up Period | Micronutrient Assessment | Prevalence of Deficiencies after Surgery | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Size | Age | Gender | |||||||||||||
|
| Years | (SD) or IQR | Male | % | Esophagectomy | Gastrectomy | Months | [IQR] | |||||||
| van Hagen et al. | Netherlands | 2017 | August 2010–July 2012 | Group A: single center, cross-sectional cohort study | 99 | 62 | 38–79 | 73 | 74 | 99 | – | 19.4 | [13.5–30.1] | Vitamin B12 | 11% |
| Group B: double center, prospective cohort study | 88 | 63 | 19–79 | 63 | 72 | 88 | – | 6.4 | [1.6–10.8] | Vitamin B12 | 10.2% | ||||
| Heneghan et al. | Ireland | 2015 | January 2013–July 2013 | Single center, prospective cohort study | 45 | 63.3 | (8.9) | 30 | 68 | 30 | 15 | 23.1 | [ | Vitamin A | 81.5% |
| Elliot et al. | Ireland | 2019 | 2000–2014 | Single center, retrospective cohort study | 75 | 60.6 | (9.6) | 58 | 77 | 75 | – | 43.4 | Missing | Vitamin A | missing |
Legend: values mean (standard deviation) or median [lower-upper quartile]. † Serum vitamin D value <50 nmol/L.
Baseline characteristics of study population.
| Clinical Characteristics | ( | |
|---|---|---|
| Sex (male) | 66 | (79.5) |
| Age at inclusion (SD) | 65 | (7.7) |
| ASA score | ||
| I | 7 | (8.4) |
| II | 63 | (75.9) |
| III | 13 | (15.7) |
| Preoperative BMI | 25.3 | (23.6–28.7) |
| Alcohol use (at inclusion) | ||
| No | 18 | (21.7) |
| Daily | 46 | (55.4) |
| Weekly | 5 | (6.0) |
| Monthly | 14 | (16.9) |
| Any comorbidity | 54 | (65.1) |
| pTNM stage | ||
| Stage 0 | 29 | (34.9) |
| Stage I | 20 | (24.1) |
| Stage II | 19 | (22.9) |
| Stage III | 15 | (18.1) |
| Histology type | ||
| Adenocarcinoma | 68 | (81.9) |
| Squamous-cell carcinoma | 15 | (18.1) |
| Tumor localization | ||
| Mid esophagus | 4 | (4.8) |
| Distal esophagus | 51 | (61.4) |
| Esophagogastric junction | 28 | (33.7) |
| Neo-adjuvant treatment | 76 | (91.6) |
| NUTRIENT II treatment allocation | ||
| Direct oral feeding | 42 | (50.6) |
| Standard of care | 41 | (49.4) |
| Any 30-day postoperative complication | 63 | (75.9) |
| BMI at discharge | 25.0 | (23.5–28.7) |
| BMI 3 months postoperatively | 23.3 | (22.0–26.9) |
Legend: values are absolute value (percentage), mean (standard deviation) or median (lower–upper quartile). BMI body mass index.
Figure 1Flowchart depicting study inclusion and follow-up measurements. Deficiencies are % of total. IQR interquartile range; Hb hemoglobin; MCV mean corpuscular volume; MMA methylmalonic acid.
Hematological and nutritional profile in postoperative follow-up.
| Measurement 1 | Measurement 2 | Measurement 3 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.1 Months (5.4–7.5) | 16.5 Months (12.2–22.1) | 24.8 Months (19.4–33.1) | |||||||||||||||||
| Micronutrient | Normal Value | Total | Abnormal Value | Total | Abnormal Value | Total | Abnormal Value | ||||||||||||
| Standard | ( | Value | (%) | Value | ( | Value | (%) | Value | ( | Value | (%) | Value | |||||||
|
| 70–200 nmol/L | 80 | 132 | (31) | – | – | – | 57 | 137 | (37) | – | – | – | 18 | 136 | (31) | 5.6 | 68 | – |
|
| 35–110 nmol/L | 80 | 75 | (58–95) | – | – | – | 57 | 81 | (64–110) | – | – | – | 18 | 67 | (54–90) | – | – | – |
|
| 140–700 pmol/L | 82 | 240 | (200–323) | 6.1 | 110 | (89–130) | 59 | 310 | (220–470) | 1.7 | 130 | – | 18 | 240 | (210–410) | – | – | – |
|
| >50 nmol/L | 81 | 48 | (36–68) | 50.6 | 36 | (29–42) | 57 | 63 | (55–74) | 19.3 | 34 | (33–41) | 17 | 63 | (55–77) | 11.8 | 47 | (45–49) |
|
| >10 nmol/L | 80 | 14 | (10–22) | 28.8 | 7 | (6–9) | 53 | 20 | (13–35) | 20.8 | 8 | (7–9) | 17 | 14 | (10–24) | 23.5 | 7 | (5–8) |
|
| 0–430 nmol/L | 77 | 230 | (186–302) | 14.3 | 569 | (482–692) | 56 | 195 | (168–246) | 5.4 | 475 | (470–611) | 16 | 220 | (173–403) | 12.5 | 721 | (667–775) |
|
| <15 μmol/L | 73 | 13 | (11–16) | 35.6 | 18 | (16–20) | 55 | 12 | (10–14) | 21.8 | 18 | (16–20) | 15 | 13 | (10–20) | 33.3 | 21 | (18–24) |
|
| |||||||||||||||||||
|
| (♂) 8.5–11.0 mmol/L | 50 | 8.6 | (8.0–8.9) | 32 | 7.7 | (7.2–8.3) | 34 | 8.6 | (8.1–8.9) | 26.5 | 7.9 | (7.7–8.3) | 11 | 8.7 | (7.7–9.3) | 18.2 | 7.6 | (7.2–7.9) |
| (♀) 7.5–10.0 mmol/L | 8.4 | (8.0–8.6) | – | – | – | 8.7 | (7.9–9.1) | – | – | – | 8.4 | (7.5–8.7) | 9.1 | 6.7 | – | ||||
|
| 80–100 fL | 44 | 91 | (87–93) | 4.5 | 80 | (79–80) | 26 | 93 | (89–96) | 11.5 | 103 | (102–108) | 9 | 90 | (88–91) | 11.1 | 68 | – |
|
| 4.5 | 101 | (100–101) | – | – | – | 11.1 | 101 | – | ||||||||||
|
| 14–35 μmol/L | 59 | 14 | (12–17) | 35.5 | 10 | (8–13) | 45 | 16 | (14–20) | 17.8 | 9 | (7–12) | 16 | 16 | (12–19) | 25 | 10 | (5–12) |
|
| 2.2–3.6 g/L | 32 | 2.6 | (2.2–2.9) | 18.8 | 2.1 | (2.0–2.2) | 18 | 2.5 | (2.1–2.8) | 33.3 | 2.0 | (1.6–2.1) | 7 | 2.8 | (2.0–3.3) | 28.6 | 2.0 | (1.9–2.0) |
|
| 30–400 μg/L | 51 | 76 | (32–180) | 19.6 | 16 | (14–23) | 40 | 94 | (33–169) | 20 | 14 | (11–24) | 9 | 32 | (25–100) | 22.2 | 19 | (13–25) |
Legend: values are mean (standard deviation) or median (lower–upper quartile). Abnormal values are % of determined (n) and always indicate a decreased value unless otherwise indicated (↓ decreased; ↑ increased). Hb hemoglobin; MCV mean corpuscular volume; MMA methylmalonic acid.